Proactive Investors - Run By Investors For Investors

4d Pharma acquisition provides for own production facilities

Biotherapeutics firm 4d Pharma PLC has bought a Spanish contract research group, which provides the group with its own production facilities. n.
Pictured - a clinical laboratory...
Alex Stevenson, 4D's chief scientific officer, said: "Over the past 12 months, we have witnessed first-hand the issues of relying on third party providers for the production of our product for clinical and development programmes.”

Biotherapeutics firm 4d Pharma PLC (LON:DDDD) has bought  a Spanish contract research group, which provides the group with its own production facilities.

Biomar, based in north-west Spain, has been an outsourced development partner of the firm since 2014 but now it has bought it for €3 million, payable on completion.

Alex Stevenson, 4D's chief scientific officer, said: "Over the past 12 months, we have witnessed first-hand the issues of relying on third party providers for the production of our product for clinical and development programmes.

"As our pace of development continues, with more of our programmes moving towards the clinic, 4D needs continued access to its own facilities to meet the challenges of our ambitious clinical development programmes, but also in looking forward to our initial production requirements."

Biomar initially focused on research into marine microorganisms, but in 2001 began to expand its technologies into microbial fermentation, providing contract services in this field and expanding its production capabilities up to 3,000 litres in 2010.

Shares eased 1.54% to 960p.

View full DDDD profile View Profile

4D Pharma Timeline

Newswire
June 10 2016

Related Articles

picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
tablets and pills
Tue
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use